Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

variants

- PMLiVE

New virtual health and care report from WHO and Novartis calls for ‘critical action’

The report analysis shows how COVID-19 has changed virtual health and care policies in 23 countries

- PMLiVE

UK report suggests last winter’s Omicron strain was less likely to cause ‘long COVID’

Data from nearly 100,000 people was gathered by a team from King’s College London

- PMLiVE

EU governments pressure manufacturers to renegotiate contracts for COVID-19 vaccines

EU officials have warned that millions of vaccine doses could be wasted due to over-supply

- PMLiVE

Eli Lilly and Incyte’s Olumiant receives FDA approval for alopecia

The treatment is the first and only systemic medicine for adults with the condition

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Moderna announces trial results for new COVID-19 booster vaccine candidate

The new vaccine candidate offers nearly twice as much protection against Omicron as Spikevax

- PMLiVE

FDA approves GSK’s Priorix vaccine for measles, mumps and rubella

The vaccine has been approved to use in those aged 12 months and above

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

Pfizer to expand Paxlovid manufacturing in US to meet global demand

The $120m investment will also create more than 250 high-skilled manufacturing jobs

- PMLiVE

Sanofi and Regeneron receives FDA priority review for prurigo nodularis

Dupixent would be the first drug specifically indicated for the condition in the US

- PMLiVE

Genentech’s Evrysdi gets extended FDA approval for spinal muscular atrophy

The drug is now approved to treat SMA in children and adults of all ages

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links